Pevion Biotech hires new ceo

Also secures CHF10m of financing

Pevion Biotech, a vaccine developer based in Berne, Switzerland, has appointed Evert Kueppers as chief executive, succeeding Thomas Stauffer.

Prior to joining Pevion, Kueppers was ceo of Pieris, a Munich-based biotechnology company, which he successfully restructured and refinanced, raising a total US$45m. Before joining the biotech industry, he spent several years in the International Operations of BASF Pharma (now Abbott Labs) and was a management consultant with the global healthcare team of AT Kearney in London.

The company has also secured further financing of CHF10m from its existing investors, BZ Bank, BB Biotech Ventures and Core Capital.

Pevion says it plans to raise additional financing over the next 12 months to broaden its pipeline.

‘Pevion has reached an important stage in its development as its candidate products reach for critical milestones. This financing commitment should take the company a long way towards achieving further product validation,’ said Joseph Manko of BZ Bank and member of the Board of Directors.

You may also like

Finance
Viral vector CDMO VintaBio’s Philadelphia facility and IP up for sale

Viral vector CDMO VintaBio’s Philadelphia facility and IP up for sale

VintaBio’s assignee is seeking bids for its cGMP facility, equipment and proprietary AAV technology as gene therapy contract manufacturers face overcapacity
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Manufacturing
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India

Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India

The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
Pharmaceutical
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics

OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics

The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
Finance
Merck KGaA divests US CDMO business to Lonza

Merck KGaA divests US CDMO business to Lonza

Merck KGaA will sell its US CDMO business to Lonza in a deal worth hundreds of millions of Swiss francs, expanding Lonza's US manufacturing footprint and marking a strategic shift for Merck
Pharmaceutical
Bavarian Nordic secures four-year UK vaccine supply contract

Bavarian Nordic secures four-year UK vaccine supply contract

The agreement with the UK Health Security Agency will see the Danish vaccine manufacturer supply its MVA-BN mpox and smallpox vaccine, supporting the UK's long-term infectious disease preparedness
Pharmaceutical
Pharma’s silent sustainability risk and the supply chain fix

Pharma’s silent sustainability risk and the supply chain fix

Pharma is making efforts to cut emissions from its own operations: shifting to renewables, upgrading facilities, streamlining logistics²⁰. But a significant share of emissions still hides outside the company’s direct control – yet in plain sight. Now, regulators and investors are turning their focus beyond the factory gates, deep into the value chain. What they’re finding is already reshaping the rules of competitiveness, capital access, and compliance. One of pharma’s most overlooked risks is quietly moving into the foreground. And the time to act is narrowing
Subscribe now